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Efficacy and safety data based on historical or 
pre-existing conditions at baseline for patients 
with active rheumatoid arthritis who were 
treated with baricitinib
Patients with rheumatoid arthritis (RA) have a high prevalence of 
comorbidities.1 This post-hoc analysis investigated the effect of 
select comorbidities (depression, osteoporosis, hepatic, cardio-
vascular or pulmonary disorders) on the efficacy and safety of 
baricitinib 4 mg once daily in patients with moderate-to-severe 
active RA and an inadequate response to conventional synthetic 
disease-modifying antirheumatic drugs (csDMARDs).
Data from the placebo-controlled periods of five baricitinib 
studies2–6 were pooled for baricitinib 4 mg; data for baricitinib 
2 mg were not analysed due to low (n=302) patient numbers. 
Additional data for all baricitinib-treated patients with a median 
exposure of 2 years were derived from an ongoing open-label, 
long-term extension (LTE) study that included patients from 
phase II and III studies (RA-BEYOND; NCT01885078).7 Effi-
cacy outcomes were evaluated at week 12 (vs placebo). Inter-
action of comorbidity-by-treatment was analysed using logistic 
regression or analysis of covariance. Safety observations up to 
week 16 (vs placebo) and during the LTE were summarised by 
the Medical Dictionary for Regulatory Activities preferred term.
Data from 1684 patients (803, baricitinib 4 mg; 881, placebo) 
from the placebo-controlled periods were analysed. The mean 
(SD) age was 52.7 (12.1) years, with only 38 (2.3%) patients 
aged ≥75 years; most patients (1506, 89.4%) were receiving 
background methotrexate, alone or in combination with another 
csDMARD. The numbers of patients receiving placebo and 
baricitinib 4 mg combined (with or without each comorbidity, 
respectively) were 133/1551 for depression, 247/1437 for oste-
oporosis, 424/1260 for hepatic disorders, 731/953 for cardio-
vascular disorders, and 166/1518 for pulmonary disorders. 
Demographic and clinical characteristics within each comor-
bidity subgroup were similar between patients randomised to 
baricitinib or placebo.
Higher proportions of patients achieved all clinical endpoints 
with baricitinib 4 mg than with placebo at week 12 across 
subgroups (table 1). Response rates in patients with or without 
each comorbidity who received baricitinib were generally close 
to overall response rates, with the exception of depression, where 
numerically lower response rates were observed in patients with 
versus without depression and overall (table 1). Responses to 
baricitinib versus placebo were similar between patients with or 
without comorbidity within each comorbidity subgroup, even 
for those with/without depression (p>0.1).
The safety analysis set from the placebo-controlled periods 
included 1683 patients (802, baricitinib; 881, placebo) with 
235.2 and 246.9 patient-years of exposure (PYE) to baricitinib 
4 mg or placebo, respectively. Similar proportions of patients 
experienced ≥1 treatment-emergent adverse events (TEAEs) 
between baricitinib and placebo across comorbidity subgroups 
(table 1). The most common TEAEs for the overall population 
were nasopharyngitis (5.6%, baricitinib vs 5.2%, placebo), upper 
respiratory tract infections (4.5% vs 3.5%), urinary tract infec-
tions (3.5% vs 2.6%) and bronchitis (2.9% vs 2.6%). Serious 
adverse events (SAEs) and discontinuations were infrequent, 
occurring at similar rates across subgroups for baricitinib and 
placebo. SAE and discontinuation rates for baricitinib-treated 
patients with/without each comorbidity were generally close 
to overall rates, although numerical differences were observed 
between patients with depression (lower rates), osteoporosis 
(higher rates) or pulmonary disorders (higher rates) and those 
without these comorbidities.
In the LTE study, safety data were available from 3439 patients 
with a total of 6633 PYE to baricitinib. Overall, the incidence of 
TEAEs, SAEs, discontinuations and reported deaths was similar 
between patients with or without comorbidity within each 
comorbidity subgroup (table 1). Further, the exposure-adjusted 
incidence rates for all patients were lower in the LTE than during 
the placebo-controlled period for all safety outcomes assessed. 
The numerical differences between patients with/without each 
comorbidity observed after 16 weeks (see above) were not 
observed in the LTE study.
This is the first analysis assessing the impact of select comor-
bidities on the efficacy and safety of baricitinib 4 mg. Limita-
tions of this post-hoc analysis include the analysis of patient data 
derived from randomised clinical trials rather than real-world 
patient data, such that patients with certain acute or historical 
conditions, unstable illness, or certain laboratory abnormalities 
were excluded from the trials (see online supplementary text); 
the limited number of patients in each comorbidity subgroup 
and the limited duration of analyses; the non-inclusion of all 
known comorbidities in RA; the mix of comorbidities included 
in each subgroup, which could vary in severity and overall 
impact on patients; the inability to assess adverse events of 
specific interest and whether comorbidity severity improved 
or worsened following baricitinib treatment; and the inability 
to conclude on the efficacy and safety of baricitinib in patients 
aged ≥75 years and/or exposed to baricitinib 2 mg due to low 
patient numbers. Planned analyses of safety data from registries 
or healthcare databases in the USA and Europe are expected to 
address many of the current limitations.
Baricitinib 4 mg showed similar efficacy and safety during 
placebo-controlled and LTE observation periods regardless of 
the presence or absence of select comorbidities in patients with 
moderate-to-severe active RA and an inadequate response to 
csDMARDs. No trends for increased risk of safety events related 
to comorbidity were observed across comorbidity subgroups for 
baricitinib during a median exposure of 2 years. Further studies 
are needed to confirm the data presented, which provide a 
hypothesis only.
Trial registration numbers: NCT01185353, NCT01469013, 
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